Zhang Hong-Li, Uticul Adina, Xu Xiao-Wei, Shi Yu-Wei
Department of Hematology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830063, China.
Department of Hematology, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830063, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Jun;30(3):784-789. doi: 10.19746/j.cnki.issn.1009-2137.2022.03.020.
To analyze the relationship between serum miR-34a level and thrombocytopenia after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
A total of 69 eligible DLBCL patients who received chemotherapy in our hospital from January 2018 to January 2020 were prospectively included as the research subjects, all patients received R-CHOP 21 regimen (rituximab + cyclophosphamide + adriamycin + vincristine + prednisone) for chemotherapy, 3 weeks was 1 cycle, and 2 cycles of chemotherapy were used. The patients were divided into a reduction group and a non reduction group according to whether there was thrombocytopenia after chemotherapy, the general data and laboratory indexes of the two groups were investigated and compared, the relationship between serum miR-34a before chemotherapy and thrombocytopenia after chemotherapy in patients was analyzed.
Among the 69 DLBCL patients, 36 patients developed thrombocytopenia after 2 cycles of R-CHOP 21 regimen for chemotherapy, the incidence was 52.17%; the level of serum IL-11 and the relative expression of miR-34a mRNA in the reduction group were significantly lower than the non reduction group (P<0.05), compared other data between groups, there was no statistical significant difference (P>0.05); after Logistic regression analysis, the results showed that the level of serum IL-11 and the relative expression of miR-34a mRNA were related to thrombocytopenia after chemotherapy in DLBCL patients, low expression of each index may be a risk factor of thrombocytopenia after chemotherapy in DLBCL patients (OR>1, P<0.05); ROC curve was drawn, and the results showed that the AUC of serum IL-11 level and miR-34a mRNA relative expression before chemotherapy alone and in combination predicted the risk of thrombocytopenia after chemotherapy in DLBCL patients were all >0.80, and the predictive value was ideal, when the cut-off value of serum IL-11 level before chemotherapy was 42.094 pg/ml, and the cut-off value of miR-34a mRNA relative expression was 3.894, the combined prediction value was the best.
The relative expression of miR-34a mRNA is associated with thrombocytopenia after chemotherapy in DLBCL patients, which may be a risk factor for thrombocytopenia in patients after chemotherapy, has certain value in predicting the risk of thrombocytopenia of patients after chemotherapy.
分析弥漫性大B细胞淋巴瘤（DLBCL）患者化疗后血清miR-34a水平与血小板减少之间的关系。
前瞻性纳入2018年1月至2020年1月在我院接受化疗的69例符合条件的DLBCL患者作为研究对象，所有患者均接受R-CHOP 21方案（利妥昔单抗+环磷酰胺+阿霉素+长春新碱+泼尼松）化疗，3周为1个周期，共进行2个周期化疗。根据化疗后是否出现血小板减少将患者分为减少组和非减少组，调查并比较两组的一般资料和实验室指标，分析化疗前患者血清miR-34a与化疗后血小板减少的关系。
69例DLBCL患者中，36例在接受2个周期R-CHOP 21方案化疗后出现血小板减少，发生率为52.17%；减少组血清IL-11水平及miR-34a mRNA相对表达量均显著低于非减少组（P<0.05），比较两组间其他数据，差异无统计学意义（P>0.05）；经Logistic回归分析，结果显示血清IL-11水平及miR-34a mRNA相对表达量与DLBCL患者化疗后血小板减少有关，各指标低表达可能是DLBCL患者化疗后血小板减少的危险因素（OR>1，P<0.05）；绘制ROC曲线，结果显示化疗前血清IL-11水平及miR-34a mRNA相对表达量单独及联合预测DLBCL患者化疗后血小板减少风险的AUC均>0.80，预测价值理想，当化疗前血清IL-11水平截断值为42.094 pg/ml，miR-34a mRNA相对表达量截断值为3.894时，联合预测价值最佳。
miR-34a mRNA相对表达量与DLBCL患者化疗后血小板减少有关，可能是患者化疗后血小板减少的危险因素，对预测患者化疗后血小板减少风险有一定价值。
